Get the latest news, insights, and market updates on LFMD (LifeMD, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Looking at the Narrative for LifeMD as Analyst Sentiment Shifts on Recent Developments
LifeMD stock has recently experienced a notable shift in its consensus analyst price target, now lowered from $12.88 to $10.63. This adjustment comes as analysts weigh both the company's recent achievements and its ongoing challenges in a dynamic telehealth landscape. Stay tuned to discover how to keep track of evolving analyst sentiment and updates on LifeMD’s market outlook. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value... Nov 19, 2025 - $LFMD
Why LifeMD (LFMD) Is Down 7.8% After Trimming Guidance Post-WorkSimpli Exit and Refocus
LifeMD reported its third-quarter 2025 results, revealing revenue of US$60.2 million and a revised full-year 2025 guidance of US$192 million to US$193 million after divesting its majority stake in WorkSimpli and refocusing as a pure-play telehealth company. Despite continued telehealth subscriber growth and operational improvements, the company’s reduced earnings outlook has intensified attention on financial performance and lingering profitability concerns. We’ll explore how LifeMD’s move... Nov 18, 2025 - $LFMD
LifeMD Reports Third Quarter 2025 Results
Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million.Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million.Paid off all outstanding debt during the quarter.Subsequent to quarter end, fully divested our majority stake in WorkSimpli, positioning LifeMD as a pure-play telehealth and pharmacy platform.Continued to diversify clinical platform with new launches in women’s health, men’s health an Nov 17, 2025 - $LFMD
LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality careNEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications, Wegovy® and Ozempic®, made possible through its ongoing collaboration with Novo Nordisk. LifeMD will now offer the 0.25 mg and 0.5 mg doses at $1 Nov 17, 2025 - $LFMD
Repare Therapeutics Inc. (RPTX) Reports Break-Even Earnings for Q3
Repare Therapeutics (RPTX) delivered earnings and revenue surprises of +100.00% and +132.40%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 14, 2025 - $LFMD
LifeMD to Participate in the BTIG Digital Health Forum
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced its participation in the virtual BTIG Digital Health Forum on November 24, 2025. Management will participate in a virtual panel discussion titled “Creating a Scalable Virtual Primary Care and Obesity Health Platform” at 4:00 p.m. Eastern time and will be available for one-on-one virtual meetings. Investors can register for the conference by co Nov 10, 2025 - $LFMD
LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects to file a Form 12b-25, as needed, notifying the U.S. Securities and Exchange Commission of a late filing of its Form 10-Q for the period ended September 30, 2025. The change to LifeMD’s third quarter 2025 Nov 5, 2025 - $LFMD
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple